Efficacy of single-dose evolocumab injection in early-phase acute myocardial infarction: a retrospective single-center study
The Korean Journal of Internal Medicine · 2024
DOI: 10.3904/kjim.2024.080 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Korean Journal of Internal Medicine, 2024. Verfasst von Yongcheol Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital, …. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Cholesterol, LDL, Anticholesteremic Agents, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background/Aims: Achieving rapid reduction of low-density lipoprotein cholesterol (LDL-C) levels below 55 mg/dL in patients with acute myocardial infarction (AMI) can be challenging with statins alone. This single-center, retrospective study aimed to assess the impact of single-dose injection of evolocumab 140 mg on LDL-C levels during the peri-percutaneous coronary intervention (PCI) period in patients with AMI.
Methods
A total of 95 patients with AMI who underwent PCI were divided into the evolocumab (n = 50) and non-evolocumab (n = 45) groups.
Results
The percentage change of LDL-C level at 1–3 weeks from baseline was 78.4 ± 13.4% reduction in the evolocumab group versus 45.6 ± 22.6% in the non-evolocumab group, with a mean difference of -33.5% between the groups (95% CI: -42.6 to -24.5%; p < 0.001). The achievement rate of LDL-C levels below 55 mg/dL at 1–3 weeks was significantly higher in the evolocumab group than in the non-evolocumab group (97.7% vs. 60.0%, p < 0.001).
Conclusions
Patients with AMI who received single-dose injection of evolocumab 140 mg during the peri-PCI period had a significantly greater LDL-C reduction and higher proportion of patients achieved the target LDL-C level in the early phase AMI than those who did not receive evolocumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital, Yongin, Korea.
- Division of Biostatistics, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea.
- Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea.
Zitieren
APA
Kim, Y., Roh, J. W., Lee, O. H., Heo, S. J., Im, E., Cho, D. K., & Kim, B. K. (2024). Efficacy of single-dose evolocumab injection in early-phase acute myocardial infarction: a retrospective single-center study. The Korean Journal of Internal Medicine. https://doi.org/10.3904/kjim.2024.080
Vancouver
Kim Y, Roh JW, Lee OH, Heo SJ, Im E, Cho DK, et al. Efficacy of single-dose evolocumab injection in early-phase acute myocardial infarction: a retrospective single-center study. The Korean Journal of Internal Medicine. 2024. doi:10.3904/kjim.2024.080
BibTeX
@article{Kim2024,
author = {Kim, Yongcheol and Roh, Ji Woong and Lee, Oh-Hyun and Heo, Seok-Jae and Im, Eui and Cho, Deok-Kyu and Kim, Byeong-Keuk},
title = {Efficacy of single-dose evolocumab injection in early-phase acute myocardial infarction: a retrospective single-center study},
journal = {The Korean Journal of Internal Medicine},
year = {2024},
doi = {10.3904/kjim.2024.080}
}
EUVIMED